Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction

Anti-Cancer Drugs

Volumn 24, Issue 8, 2013, Pages 818-825

  Leblond, Pierre ^a,b   Dewitte, Amélie ^a,b   Le Tinier, Florence ^a,b   Bal Mahieu, Christine ^a,b   Baroncini, Marc ^c   Sarrazin, Thierry ^a   Lartigau, Eric ^a   Lansiaux, Amélie ^a,b   Meignan, Samuel ^a,b  

^a UNIV LILLE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

child; Cilengitide; glioma; integrin; ionizing radiations; neuroblastoma

Indexed keywords

ALPHAVBETA5 INTEGRIN; CILENGITIDE; POLYMACON; VITRONECTIN RECEPTOR;

ANOIKIS; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL DETACHMENT; CELL FUNCTION; CELL GROWTH; CHILDHOOD CANCER; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGE FACTORS; ANOIKIS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASM GRADING; NEUROBLASTOMA; RADIOTHERAPY, ADJUVANT; RECEPTORS, VITRONECTIN; SNAKE VENOMS; TIME FACTORS;

EID: 84881040930     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328362edc5     Document Type: Article

References (32)

1. Terracini B, Coebergh JW, Gatta G, Magnani C, Stiller C, Verdecchia A, et al. Childhood cancer survival in Europe: an overview. Eur J Cancer 2001; 37:810-816.
2. Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neurol Oncol 2011; 13:109-118.
3. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neurol Oncol 2011; 13:298-306.
4. Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neurol Oncol 2011; 13:290-297.
5. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neurol Oncol 2007; 9:145-160.
6. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28:3069-3075.
7. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007; 25:1637-1638.
8. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep 2006; 8:96-103.
9. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, et al. Alpha v-integrin antagonist EMD121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98: 690-697.
10. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006; 13:113-135.
11. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46:135-144.
12. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-571.
13. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270:1500-1502.
14. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93:9764-9769.
15. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD121974) on glioblastoma growth in nude mice. Neurosurgery 2006; 59:1304-1312, discussion 1312.
16. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, et al. Bimodal anti-glioma mechanisms of Cilengitide demonstrated by novel invasive glioma models. Neuropathology 2012; 33:162-174.
17. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, et al. Integrin control of the transforming growth factor-beta pathway in glioblastoma. Brain 2013; 136:564-576.
18. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of Cilengitide and temozolomide with concomitant radiotherapy followed by Cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:2712-2718.
19. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28:3061-3068.
20. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 2009; 4:e5209.
21. MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neurol Oncol 2011; 13:1049-1058.
22. Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009; 27:1014-1019.
23. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. Alpha v beta 3 and alpha v beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6:105-119.
24. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008; 27:86.
25. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48:151-157.
26. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neurol Oncol 2009; 11:747-756.
27. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42:3033-3040.
28. Lomonaco SL, Finniss S, Xiang C, Lee HK, Jiang W, Lemke N, et al. Cilengitide induces autophagy-mediated cell death in glioma cells. Neurol Oncol 2011; 13:857-865.
29. Westhoff MA, Zhou S, Bachem MG, Debatin KM, Fulda S. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 2008; 27:5169-5181.
30. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006; 65:1536-1543.
31. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, et al. Radiation sensitization of glioblastoma by Cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124:2719-2727.
32. Kim YH, Lee JK, Kim B, Dewitt JP, Lee JE, Han JH, et al. Combination therapy of Cilengitide with belotecan against experimental glioblastoma. Int J Cancer 2013 [Epub ahead of print].